{"disease":{"id":"biliary-malignant-tumors","name":"biliary malignant tumors"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06685289","title":"Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT04060472","title":"Paclitaxel (Albumin-bound) and Oxaliplatin for Advanced Hepatobiliary and Malignant Tumors","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":57,"lead_sponsor_name":"Dong Wang","has_results":false},{"nct_id":"NCT04660929","title":"CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Carisma Therapeutics Inc","has_results":false},{"nct_id":"NCT07368803","title":"Evaluation of the Safety, Tolerability and Efficacy of iNeo-Vac-R01, an Individualized mRNA Therapeutic Technology Based on Tumor Neoantigens, for Adjuvant Treatment in Patients With Biliary Malignant Tumors After Radical Resection","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Yifan Wang","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}